Mitchell J

Ethical Legal Implications of Psychedelics in Society Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston.

1 preprint · 7 papers · ORCID

PreprintPsychedelics

Tales of the unexpected: psychedelic trial design solutions

Carhart-Harris R, Lucas WA, Pasquini L +4

Europe PMC2026
ArticleKetamine

When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities.

Mitchell J, Bregman B, Surujnarain R +2

Europe PMC2026
ArticlePsilocybin

From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.

Mitchell J, Neitzke-Spruill L, Mathai DS +4

Europe PMC2026
ArticlePsilocybin

Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia's clinical landscape.

Dutton M, Schwenn P, Mitchell J +5

Europe PMC2026
ArticlePsilocybin

Psilocybin-assisted therapy and HIV-related shame.

Mehtani NJ, Johnson MO, Hendricks PS +2

Europe PMC2024
ArticlePsilocybin

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.

Levin A, Nagib PB, Deiparine S +3

Europe PMC2022
ArticlePsilocybin

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

De Gregorio D, Aguilar-Valles A, Preller KH +4

Europe PMC2021
ArticlePsilocybin

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

Anderson BT, Danforth A, Daroff PR +8

Europe PMC2020